| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 333.95M | 333.94M | 344.55M | 323.88M | 228.71M | 158.06M |
| Gross Profit | 88.21M | 307.69M | 312.49M | 80.35M | 42.38M | 42.99M |
| EBITDA | 65.18M | 67.82M | 74.55M | 70.48M | 45.64M | 25.95M |
| Net Income | 42.22M | 42.22M | 50.71M | 46.78M | 27.18M | 14.20M |
Balance Sheet | ||||||
| Total Assets | 241.08M | 241.08M | 217.04M | 219.83M | 224.12M | 169.66M |
| Cash, Cash Equivalents and Short-Term Investments | 79.67M | 79.67M | 68.19M | 82.41M | 100.95M | 76.84M |
| Total Debt | 16.42M | 16.42M | 12.33M | 15.70M | 16.65M | 17.90M |
| Total Liabilities | 90.61M | 90.61M | 89.60M | 106.87M | 124.45M | 81.99M |
| Stockholders Equity | 151.87M | 151.87M | 128.06M | 114.64M | 100.50M | 88.38M |
Cash Flow | ||||||
| Free Cash Flow | 35.60M | 35.24M | 26.76M | 15.38M | 37.72M | -15.82M |
| Operating Cash Flow | 37.56M | 37.21M | 27.84M | 19.79M | 41.68M | -12.91M |
| Investing Cash Flow | -1.98M | -922.21K | 1.26M | -4.45M | 655.17K | -2.61M |
| Financing Cash Flow | -24.76M | -24.76M | -40.38M | -34.05M | -18.51M | -11.74M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | AU$587.44M | 14.02 | 29.67% | 2.51% | -3.08% | -16.35% | |
74 Outperform | AU$526.01M | 22.42 | 34.21% | 2.25% | 3.10% | 5.08% | |
73 Outperform | AU$1.17B | 32.78 | 25.18% | 0.57% | 36.30% | 82.20% | |
71 Outperform | AU$726.70M | 20.92 | 50.61% | 5.24% | 12.96% | 8.19% | |
69 Neutral | AU$336.49M | 14.27 | 16.13% | 5.71% | 25.14% | -14.54% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
Lycopodium Limited addressed a late lodgment of Appendices 3Y related to changes in directors’ securities holdings, attributing the delay to an administrative oversight. The company emphasized its commitment to compliance with ASX Listing Rules through existing policies and communication with directors, ensuring such oversights are unlikely to recur.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.
Lycopodium Limited announced a change in the director’s interest, with Director Peter De Leo selling 30,000 ordinary shares valued at $390,000. This transaction, conducted as an on-market sale, reduces his holding to 909,053 fully paid ordinary shares. Such changes in director’s interests can impact investor perception and reflect strategic financial decisions by company leadership.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.
Lycopodium Limited has announced the issuance of 372,392 ordinary fully paid securities as of December 1, 2025. This move reflects the company’s ongoing financial strategies and could potentially impact its market positioning by enhancing its capital structure and supporting future growth initiatives.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.
Lycopodium Limited announced a change in the director’s interest, with Bruno Ruggiero acquiring additional shares through the vesting of performance rights. This change reflects the director’s increased stake in the company, potentially signaling confidence in the company’s future performance and aligning the director’s interests with those of the shareholders.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.
Lycopodium Limited has announced a change in the director’s interest notice for Peter De Leo. The change involves the conversion of Class A Performance Rights into fully paid ordinary shares, increasing De Leo’s holdings to 939,053 shares and reducing his performance rights to 42,848. This adjustment in the director’s interests reflects internal financial movements within the company, potentially impacting shareholder perceptions and the company’s governance transparency.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.
Lycopodium Limited has announced a change in the director’s interest notice, specifically for Director Karl Cicanese. The change involves the acquisition of 12,544 Class A Performance Rights under the company’s Incentive Performance Rights Plan, as approved at the 2025 Annual General Meeting. This adjustment reflects the company’s ongoing commitment to aligning director incentives with performance objectives, potentially impacting the company’s governance and stakeholder relations.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.
Lycopodium Limited has announced a change in the director’s interest notice, specifically regarding Bruno Ruggiero. The change involves the acquisition of 11,836 Class A Performance Rights under the company’s Incentive Performance Rights Plan, as approved at the 2025 AGM. This adjustment reflects the company’s ongoing commitment to aligning director incentives with company performance, potentially impacting stakeholder perceptions positively.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.
Lycopodium Limited announced a change in the director’s interest, specifically regarding Peter De Leo, who acquired additional Class A Performance Rights under the company’s Incentive Performance Rights Plan. This change reflects the company’s ongoing commitment to aligning director incentives with corporate performance, potentially impacting shareholder value and company operations positively.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.
Lycopodium Limited held its FY2025 Annual General Meeting on 13 November 2025, where key resolutions were passed. The meeting included the adoption of the Remuneration Report and the election and re-election of directors, with all motions carried successfully. These outcomes reflect the company’s stable governance and continued focus on strategic leadership, which may positively impact its operations and stakeholder confidence.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.
Lycopodium Limited has released its FY25 Sustainability Report, highlighting its commitment to sustainable practices and alignment with the United Nations Sustainable Development Goals. The report outlines the company’s governance, risk management strategies, and performance metrics, emphasizing its efforts to manage environmental and social impacts. This announcement underscores Lycopodium’s dedication to integrating sustainability into its operations, potentially enhancing its industry positioning and stakeholder relations.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.
Lycopodium Limited announced a significant change in the interest of its director, Karl Cicanese, who sold 200,000 fully paid ordinary shares valued at $2,550,000, reducing his holdings to 200 shares. This transaction reflects a notable shift in the director’s investment position, potentially impacting stakeholder perceptions and the company’s market dynamics.
The most recent analyst rating on (AU:LYL) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Lycopodium Limited stock, see the AU:LYL Stock Forecast page.